Inari Medical, Inc. (NASDAQ:NARI – Get Rating) COO Andrew Hykes sold 9,000 shares of the business’s stock in a transaction dated Monday, November 21st. The shares were sold at an average price of $77.66, for a total value of $698,940.00. Following the sale, the chief operating officer now owns 111,998 shares of the company’s stock, valued at $8,697,764.68. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Andrew Hykes also recently made the following trade(s):
- On Thursday, October 20th, Andrew Hykes sold 9,000 shares of Inari Medical stock. The shares were sold at an average price of $72.33, for a total value of $650,970.00.
- On Tuesday, September 6th, Andrew Hykes sold 5,000 shares of Inari Medical stock. The shares were sold at an average price of $70.00, for a total value of $350,000.00.
Inari Medical Price Performance
Shares of NARI opened at $75.75 on Friday. The stock has a market capitalization of $4.06 billion, a price-to-earnings ratio of -180.36 and a beta of 1.21. Inari Medical, Inc. has a 1 year low of $50.50 and a 1 year high of $100.00. The business’s 50 day simple moving average is $73.75 and its 200-day simple moving average is $71.43.
Analyst Upgrades and Downgrades
Institutional Trading of Inari Medical
Hedge funds have recently modified their holdings of the company. Trustcore Financial Services LLC raised its holdings in shares of Inari Medical by 266.7% during the 1st quarter. Trustcore Financial Services LLC now owns 275 shares of the company’s stock worth $25,000 after acquiring an additional 200 shares in the last quarter. Parkside Financial Bank & Trust purchased a new stake in shares of Inari Medical during the 1st quarter worth approximately $25,000. Fifth Third Bancorp purchased a new stake in shares of Inari Medical during the 2nd quarter worth approximately $27,000. Canada Pension Plan Investment Board raised its holdings in Inari Medical by 40.9% during the 3rd quarter. Canada Pension Plan Investment Board now owns 689 shares of the company’s stock valued at $50,000 after buying an additional 200 shares during the period. Finally, DB Wealth Management Group LLC purchased a new stake in Inari Medical during the 1st quarter valued at $54,000. 84.11% of the stock is owned by hedge funds and other institutional investors.
About Inari Medical
Inari Medical, Inc, a medical device company, develops, manufactures, markets, and sells devices for the interventional treatment of venous diseases in the United States. The company provides ClotTriever, a mechanical thrombectomy system, which is designed to core, capture, and remove large clots from large vessels, as well as for treatment of deep vein thrombosis; and FlowTriever, a large bore catheter-based aspiration and mechanical thrombectomy system, for treatment of pulmonary embolism.
- Get a free copy of the StockNews.com research report on Inari Medical (NARI)
- Three CBD Stocks to Dominate a Budding Industry
- Is the 60/40 Portfolio Mix Still in Vogue?
- Institutional Support for Analog Devices Remains High
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Microsoft Shares: Is it Time to Back Up the Truck?
Receive News & Ratings for Inari Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inari Medical and related companies with MarketBeat.com's FREE daily email newsletter.